The risk of local and regional relapse associated with each breast cancer molecular subtype was determined in a large cohort of patients with breast cancer. Subtype assignment was accomplished using a validated six-marker immunohistochemical panel applied to tissue microarrays.
INTRODUCTION
In the contemporary management of breast cancer, several possibilities exist for local and regional treatment. Patients and their oncologists must decide between various surgical options and the dose, volume, and technique of radiotherapy. These decisions may have a significant impact on treatment-related morbidity and survival from breast cancer. [1] [2] [3] [4] A better understanding of the risk of local relapse (LR) and regional relapse (RR) would facilitate therapeutic decision making.
Gene expression profiling can be used to separate breast cancers into distinct molecular subtypes with prognostic significance. [5] [6] [7] [8] Commercially available assays based on gene expression profiling, including Oncotype DX (Genomic Health, Redwood City, CA) and MammaPrint (Agendia, Amsterdam, the Netherlands), may provide useful prognostic information. 9, 10 Other studies have found that using immunohistochemical surrogates for molecular subtyping can provide much of the prognostic information obtained by gene expression profiling. [11] [12] [13] Although most studies of molecular subtypes in breast cancer report differences in survival, few have examined the differences in locoregional recurrence. The influence of breast cancer molecular subtypes on locoregional relapse and their relevance compared with established clinicopathologic JOURNAL OF CLINICAL ONCOLOGY variables has not been defined. Biomarker studies can provide prognostic information that may facilitate treatment decisions. In this study, we describe the effect of breast cancer subtypes on LR and RR in a large cohort of patients with early breast cancer.
PATIENTS AND METHODS

Study Population
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For the local treatment of breast cancer, patients underwent either breast-conserving surgery (BCS) followed by adjuvant radiotherapy or mastectomy. Patients treated with BCS who did not receive adjuvant radiotherapy and patients with positive surgical margins were excluded from analysis. Patients typically had a level II axillary dissection, and the mean number of lymph nodes dissected was 11 nodes. Patients who underwent mastectomy may have received adjuvant radiotherapy at the discretion of the oncologist. In most cases, postmastectomy radiotherapy was limited to patients with high-risk disease (T3 tumors, Ͼ three involved lymph nodes, or any lymph node Ͼ 2 cm). Most patients were treated with adjuvant systemic therapy according to provincial management guidelines established by the BCCA.
14 No patients in this cohort were treated with neoadjuvant chemotherapy or adjuvant trastuzumab. This study was approved by the Clinical Research Ethics Board of the University of British Columbia and the BCCA.
Tissue Microarrays and Immunohistochemistry
Tissue cores were extracted from archival blocks of the primary breast tumor and used to construct a tissue microarray as previously described.
15
Immunohistochemical staining was performed for the biomarkers of ER, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), Ki-67, epidermal growth factor receptor (EGFR), and cytokeratin (CK) 5/6 on each of the tissue microarray slides using the standard streptavidin-biotin complex method with 3Ј3Јdiaminobenzidine chromogen. Staining and interpretation of ER, PR, HER2, Ki-67, EGFR, and CK5/6 have been previously described.
12,13 Surgical pathologists scoring the tissue microarrays were blinded to the clinicopathologic characteristics and outcome of each patient. Samples with less than 50 tumor cells present in the tissue microarray cores were considered uninterpretable and were excluded from analysis. All of the stained tissue microarrays were digitally scanned, and primary image data are available for public access (http://www.gpecimage.ubc .ca/tma/web/viewer.php; username: localrecur; password: localrecur).
Breast cancer molecular subtypes according to immunohistochemical profile were categorized as follows: luminal A (ER positive or PR positive and Ki-67 Ͻ 14%; Table 1 ), luminal B (ER positive or PR positive and Ki-67 Ն 14%), luminal-HER2 (ER positive or PR positive and HER2 positive), HER2 enriched (ER negative, PR negative, and HER2 positive), and basallike (ER negative, PR negative, HER2 negative, and EFGR positive or CK5/6 positive). In addition triple-negative tumors (triple negative phenotype [TNP]) that were negative for both EGFR and CK5/6 were labeled TNP-nonbasal.
Statistical Analysis
All statistical analyses were carried out using SPSS Version 16.0 (SPSS, Chicago, IL) and R 2.8.1 (http://www.r-project.org). Differences in the clinicopathologic features between patients assigned to the six breast cancer molecular subtypes were examined using 2 tests. To avoid confounding factors related to locoregional therapy, survival analyses were conducted separately for patients treated with BCS versus mastectomy. Because the clinical implications and therapeutic options differ after LR or RR, we also chose to analyze these events separately. LR was defined as disease recurrence within the ipsilateral breast or chest wall. RR was defined as disease recurrence in the ipsilateral axillary nodes, internal mammary nodes, or supraclavicular nodes. Patients were censored at the time of last follow-up, at the date of distant relapse, or at the time of death.
For univariable survival analysis, LR-free survival (LRFS) and RR-free survival (RRFS) were estimated using Kaplan-Meier curves, and survival differences were assessed using log-rank tests. Cox proportional hazards models were used to calculate adjusted hazard ratios accounting for covariates. Clinicopathologic covariates included age at diagnosis, tumor size, tumor grade, presence of lymphovascular invasion, and lymph node status.
16,17 Treatment covariates included chest wall radiotherapy (for LR analysis after mastectomy only), nodal irradiation (for RR analysis only), boost irradiation (for LR after breast conservation only), chemotherapy, and hormonal therapy. Smoothed plots of weighted Schoenfeld residuals were used to test proportional hazard assumptions.
18 All statistical tests were two-sided, and P Ͻ .05 was considered statistically significant.
RESULTS
The Patient Cohort
Of 4,033 patients with nonmetastatic, newly diagnosed breast cancer, 59 were excluded because they had no primary surgery, and 133 patients were excluded because they had BCS without adjuvant breast radiotherapy. Four hundred six patients had positive surgical margins after BCS, and these patients were also excluded. Four hundred seventy-six patients were excluded because missing biomarker scores did not allow for assignment to a molecular subtype. In the final cohort of 2,985 tumors, the median age was 59 years, and median follow-up time for both LR and RR was 12 years. For patients treated with BCS, there were 130 LR events and 83 RR events. After mastectomy, there were 195 LR events and 144 RR events. The majority of these patients had luminal A tumors (44%, 1,305 of 2,985 patients), followed by luminal B (24%, 720 of 2,985 patients), basal-like (10%, 296 of 2,985 patients), HER2-enriched (8%, 227 of 2,985 patients), and luminal-HER2 tumors (6%, 185 of 2,985 patients). Nine percent of patients (261 of 2,985 patients) had TNP-nonbasal tumors. The clinicopathologic features are listed in Table 2 , and there were significant differences in median age, tumor size, tumor grade, lymphovascular invasion, and node status between the subtype cohorts.
Forty-two percent of patients underwent BCS, and 58% underwent mastectomy; 25% of patients treated with mastectomy received postoperative radiotherapy. Fifty-seven percent of the total cohort of patients received adjuvant systemic therapy, consisting of chemotherapy (20%), hormonal therapy (31%), or both (7%). Patients undergoing mastectomy had larger and higher grade tumors and were more likely to have lymphovascular invasion and involved lymph nodes (Table 3) .
LR and RR After BCS
Univariate survival analysis of patients treated with BCS and radiotherapy revealed statistically significant differences in LR ( Fig  1A) and RR (Fig 1B) among the molecular breast cancer subtypes (Tables 4 and 5 ). For both LR and RR, patients with luminal A tumors had the most favorable prognosis, with LR and RR rates of only 8% and 3% at 10 years, respectively. Conversely, HER2-enriched and basal-like groups exhibited the highest rates of LR (21% and 14%, respectively) and RR (16% and 14%, respectively).
Multivariable Cox analysis revealed that young age at diagnosis and the HER2-enriched subtype were independent predictors of LR (Table 6 ) and that anthracycline-based chemotherapy was protective. Multivariable Cox analysis of RR demonstrated that age less than 40 years, more than three positive lymph nodes, and HER2-enriched and basal-like breast cancer subtypes were the strongest independent predictors of recurrence in the regional lymph nodes (Table 6 ).
LR and RR After Mastectomy
Locoregional relapse patterns observed among the various breast cancer subtypes were similar between BCS and mastectomy groups. In univariate analysis, statistically significant differences in LR and RR were observed (Fig 2; Tables 7 and 8 ). After treatment with mastectomy, patients with luminal A tumors again had the best prognosis, with relatively low rates of LR and RR (8% and 4%, respectively, at 10 years). All non-luminal A subtypes exhibited a greater risk of LR and RR.
Multivariable Cox analysis of LR in patients treated with mastectomy revealed that larger tumor size, high tumor grade, positive lymph nodes, and all non-luminal A subtypes (except TNP-nonbasal) were statistically significant independent predictors of a chest wall recurrence (Table 9 ). Chemotherapy and hormonal therapy were protective against LR. All of the non-luminal A subtypes (except for TNP-nonbasal) were also found to be independent predictors of a regional nodal recurrence after mastectomy (Table 9) . (A) Univariate analysis of local relapse-free survival in patients treated with breast-conserving therapy reveals significant differences among breast cancer intrinsic subtypes (log-rank test, P ϭ .00515). (B) Univariate analysis of regional relapse-free survival among patients treated with breast-conserving therapy reveals statistically significant differences among breast cancer intrinsic subtypes (log-rank test, P Ͻ .001). Violet line, luminal A; light blue, luminal human epidermal growth factor receptor 2 (HER2); dark blue, luminal B; gold, five-marker negative phenotype; red, basal; beige, HER2 enriched. Multivariable analysis for LR and RR in both treatment subgroups was repeated using a competing risks analysis (Appendix, online only). The breast cancer subtype hazard ratios obtained from competing risks analysis were consistent with those from the Cox model. Exploratory Kaplan-Meier analysis of patients who would generally not receive adjuvant radiation was performed to identify subgroups at high risk of locoregional relapse (Appendix).
DISCUSSION
In this study, the relevance of breast cancer subtypes as predictors of LR and RR was demonstrated. Multivariable analysis illustrates the independent prognostic value of tumor subtypes compared with established clinicopathologic variables. To date, relatively few studies have attempted to find an association between breast cancer molecular subtype and locoregional recurrence. Millar et al 19 used a similar five-marker immunopanel to subclassify 495 mostly low-risk breast cancers treated with BCS. Combining LR and RR (34 events), they found a 5-year locoregional recurrence rate of 15% for HER2-enriched tumors compared with 1% for luminal A tumors (statistically significant on univariable analysis).
Nguyen et al 20 examined a contemporary cohort of 793 patients with breast cancer treated with BCS. With 18 local events, the study found that HER2-enriched and TNP tumors were associated with an increased risk of local recurrence on multivariable analysis. Haffty et al 21 observed a higher overall incidence of local recurrence in a cohort (A) Univariate analysis of local relapse-free survival after mastectomy by breast cancer subtypes reveals statistically significant differences (log-rank test, P Ͻ .001). (B) Univariate analysis of regional relapse-free survival after mastectomy reveals statistically significant differences (log-rank test, P Ͻ .001). Violet line, luminal A; light blue, luminal human epidermal growth factor receptor 2 (HER2); dark blue, luminal B; gold, five-marker negative phenotype; red, basal; beige, HER2 enriched.
of 482 patients treated with BCS. LR rate was 17% at 5 years, with no difference between TNP and non-TNP breast cancers. There was a small, but statistically significant, difference in nodal recurrence, with a higher risk observed in TNP cancers versus non-TNP cancers (5-year nodal recurrence rate of 6% v 1%, respectively). Dent et al 22 also did not find a difference in local recurrence rates for TNP breast cancer in 1,601 patients.
For patients treated with mastectomy, the Danish Breast Cancer Cooperative Group analyzed the prognostic and predictive value of ER, PR, and HER2 in 1,000 patients enrolled onto the Danish 82b and 82c postmastectomy radiation studies. [23] [24] [25] The Danish trials, in addition to a study from British Columbia, 26 were important studies that demonstrated an improvement in overall survival with postmastectomy radiotherapy. The Danish Breast Cancer Cooperative Group found that the TNP and HER2 (ER negative/PR negative/HER2 positive) subtypes were independent predictors of locoregional relapse. They also found that the survival benefit associated with postmastectomy radiation seemed to be isolated to ER-and PR-positive tumors, and there was no survival benefit for TNP and HER2-positive subtypes, suggesting that biomarkers may have a predictive role for radiotherapy response.
The current study represents the largest biomarker analysis of LR and RR in breast cancer reported to date. Luminal A tumors were associated with a low rate of LR of 8% at 10 years after either BCS or mastectomy. This result is concordant with repeated observations that luminal A tumors exhibit the best prognosis with respect to survival. 6, 7 Given that only 46% of ER-positive patients were treated with adjuvant tamoxifen in this cohort, an even lower rate of relapse may be expected with more modern adjuvant hormonal therapy. Luminal A tumors also had infrequent RR (RR rate of 3% at 10 years for both BCS and mastectomy).
After BCS and adjuvant radiotherapy, there were statistically significant differences in LR observed in the other breast cancer subtypes. Of particular concern was the high rate of LR observed in the HER2-enriched subgroup (10-year LR rate, 21% for HER2 enriched v 8% for luminal A); this LR rate approaches the in-breast recurrence rate expected for patients treated with partial mastectomy alone, without adjuvant radiotherapy. Although this subgroup was small (n ϭ 80), the HER2 subtype was an independent marker of LR after BCS (hazard ratio ϭ 2.7, P ϭ .0019). It is important to note that in the current treatment of breast cancer, adjuvant trastuzumab would certainly reduce the risk of LR. There is insufficient evidence from this study to suggest that breast conservation is inappropriate for HER2-enriched tumors, but a radiation boost may be appropriate for some patients in this cohort, particularly if other highrisk local features exist. Differences in LR among the molecular subtypes were more evident for patients treated with mastectomy. Although patients with luminal A tumors had a favorable prognosis (LR rate of 8% at 10 years), all other molecular subtypes displayed a higher rate of LR (13% to 20%). This was statistically significant on multivariable analysis for all non-luminal A tumors (except TNP-nonbasal). Currently, postmastectomy radiotherapy may be offered to patients with Nϩ or T3N0 disease and may also be beneficial in high-risk patients with T2N0 disease. 4, 27 In the subgroup of patients with grade 3 and T1-2N0-1 breast cancer, LR rate after mastectomy only was 8% for luminal A tumors compared with 22% for luminal B tumors, suggesting that these patients may benefit from additional adjuvant treatment.
RR was rare for patients with luminal A tumors. Some studies have examined the omission of axillary node sampling for low-risk populations, and our study can provide additional criteria to aid in decision making if this option is being considered. 28, 29 In our study, luminal B, luminal-HER2, HER2-enriched, and basal-like subtypes were associated with a higher risk of RR after BCS or mastectomy (as high as 20%). This was statistically significant on multivariate analysis for both treatment groups, with the exception of luminal B and luminal-HER2 tumors treated with BCS. In a subgroup of patients with grade 3, T2N0-1 breast cancer who did not receive radiotherapy to the regional lymph nodes, RR rate was 8% for luminal A tumors compared with 20% for basal tumors. Currently, the management of the axilla in breast cancer remains a challenging clinical decision; the impact of locoregional treatment on survival remains controversial, and there is the potential for significant morbidity, including arm lymphedema and neurologic injury. Although previous studies have suggested that basal breast cancers are associated with lymph node-negative disease at presentation, 30, 31 we observed a high rate of regional nodal recurrence in this subtype.
An important finding of this study was the high risk of locoregional relapse observed in luminal B tumors, identified using Ki-67. Previous studies have applied HER2-positive status alone to identify higher risk tumors among the hormone receptor-positive breast cancers, and our results suggest that this is insufficient. Using a cutoff of 14% for Ki-67, we found that luminal B tumors were the second largest molecular subtype (35% of hormone receptor-positive and HER2-negative tumors), and they were associated with significantly higher rates of LR and RR. Consistent with our results, Colleoni et al 32 found that high Ki-67 predicted for recurrence in small (Ͻ 1 cm), node-negative breast cancers. Furthermore, Mamounas et al 33 found that 25% of a cohort of ER-positive, node-negative breast cancers had a high-risk recurrence score (Oncotype DX assay), and this subgroup had a much higher risk of locoregional relapse compared with low-risk tumors (16% v 4%, respectively).
Studies looking at individual biomarkers also support the results of this study. p53 overexpression, a marker of basal-like breast tumors, is associated with local recurrence in both breast cancer [34] [35] [36] and ductal carcinoma in situ. 37, 38 Elkhuizen et al 39 found that high expression of Ki-67, a luminal B marker, is also associated with an increased risk of local recurrence, whereas Jager et al 40 found that bcl-2 expression, a marker of the luminal A subtype, is associated with a lower risk of local recurrence.
A major limitation of this study is the underuse of systemic therapy, including the absence of adjuvant trastuzumab, in this cohort. Our results from multivariable analysis demonstrate the effectiveness of systemic therapy in reducing the risk of locoregional relapse. It follows that the differences in locoregional relapse between the molecular subtypes will likely be diminished in a population receiving modern systemic therapy. In addition, although the patient subgroup treated with mastectomy only provides the best insight into the locoregional behavior of the breast cancer subtypes, these patients are not directly comparable to the much higher risk subgroup treated with mastectomy and radiation therapy. Consequently, this study is not able to generate any substantial conclusions regarding the relative radiosensitivity and predictive value of breast cancer subtypes.
We have demonstrated that a small panel of immunohistochemical markers can identify patients at increased risk of LR and/or RR. However, the biology underlying these observations remains poorly understood. Nuyten et al 41 obtained gene expression data on 161 patients treated with BCS. Using a 380-gene list, they were able to isolate a subgroup of patients at high risk for local recurrence, and this classification was found to be prognostic on multivariable analysis. This work suggests that we will be able to identify the underlying biologic mechanisms associated with local tumor aggressiveness, nodal metastasis, and radiation response. Additional studies will be required to identify the most effective treatment modality to address a greater risk of locoregional relapse; these treatments could include more extensive surgery, systemic therapy, or radiotherapy. Because effective treatment modalities exist for the locoregional control of breast cancer, further investigation into breast cancer biomarkers, molecular subtypes, and the associated risk of locoregional relapse may profoundly affect the treatment of breast cancer.
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